Trial · NCT02761057
Results by group276
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 276
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Sunitinib | 5.6 | 95% Confidence Interval 2.9 to 6.7 | months | |
| Progression Free Survival (PFS) | Cabozantinib | 9.0 | 95% Confidence Interval 5.6 to 12.4 | months | |
| Progression Free Survival (PFS) | Crizotinib | 2.8 | 95% Confidence Interval 2.6 to 3.6 | months | |
| Progression Free Survival (PFS) | Savolitinib | 3.0 | 95% Confidence Interval 2.8 to 7.2 | months | |
| Response Rate (RR) | Sunitinib | 4.35 | percentage of participants | ||
| Response Rate (RR) | Cabozantinib | 22.73 | percentage of participants | ||
| Response Rate (RR) | Crizotinib | 0 | percentage of participants | ||
| Response Rate (RR) | Savolitinib | 3.45 | percentage of participants | ||
| Overall Survival (OS) | Sunitinib | 16.4 | 95% Confidence Interval 12.8 to 21.6 | months | |
| Overall Survival (OS) | Cabozantinib | 20.0 | 95% Confidence Interval 11.3 to NA | months | |
| Overall Survival (OS) | Crizotinib | 19.9 | 95% Confidence Interval 11.2 to NA | months | |
| Overall Survival (OS) | Savolitinib | 11.7 | 95% Confidence Interval 6.7 to 28.9 | months | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sunitinib | Abdominal pain | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cabozantinib | Abdominal pain | 3 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Crizotinib | Abdominal pain | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Savolitinib | Abdominal pain | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sunitinib | Acute kidney injury | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cabozantinib | Acute kidney injury | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Crizotinib | Acute kidney injury | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Savolitinib | Acute kidney injury | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02761057/results